@article{e0016f1b1e49465eb8c7ed7588070376,
title = "Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response.",
author = "Philip Mease and Genovese, \{Mark C\} and Weinblatt, \{Michael E\} and Peloso, \{Paul M\} and Kun Chen and Othman, \{Ahmed A\} and Yihan Li and Mansikka, \{Heikki T\} and Amit Khatri and Neil Wishart and John Liu",
note = "OBJECTIVE: This study investigated the safety and efficacy of ABT-122, a TNF- and IL-17A-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) with an inadequate response to methotrexate. METHODS: Patients (N=240) were randomized to receive ABT-122 (120 or 240 mg every week), adalimumab (40 mg every other week), or placebo in a 12-week, double-blind, parallel-group study (NCT02349451).",
year = "2018",
month = jan,
day = "1",
language = "American English",
journal = "Arthritis Rheumatism",
}